An inhibitor of eukaryotic translation initiation factor 4A, CR-1–31B, has a synergistic effect on inhibiting the growth of tumor cells and inducing apoptosis in drug combination therapy (Kong et al., 2019). The gene discussed is CR1; the disease is neoplasm.